ATRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Antares Pharma's share price is $5.59. Antares Pharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2022 was $0.17. Hence, Antares Pharma's Price-to-Operating-Cash-Flow Ratio for today is 32.88.
The historical rank and industry rank for Antares Pharma's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 13 years, Antares Pharma's highest Price-to-Operating-Cash-Flow Ratio was 77.14. The lowest was 15.00. And the median was 35.51.
Antares Pharma's Cash Flow from Operations per share for the three months ended in Mar. 2022 was $-0.03. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2022 was $0.17.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Antares Pharma was 65.00% per year.
During the past 13 years, Antares Pharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 49.40% per year. The lowest was -116.20% per year. And the median was 14.20% per year.
The historical data trend for Antares Pharma's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antares Pharma Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | 31.92 | 17.00 |
Antares Pharma Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | 39.90 | 36.95 | 18.57 | 17.00 | 24.12 |
For the Medical Instruments & Supplies subindustry, Antares Pharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Antares Pharma's Price-to-Operating-Cash-Flow falls into.
Antares Pharma's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 5.59 | / | 0.17 | |
= | 32.88 |
Antares Pharma's Share Price of today is $5.59.
Antares Pharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Antares Pharma's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Carmen B Volkart | director | C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127 |
Peter C Richardson | officer: See Remarks | 28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
Fred M Powell | officer: Executive Vice President & CFO | C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
Thomas J Garrity | director | |
Roche Robert P Jr | director | 41 MOORES ROAD FRAZER PA 19355 |
Leonard S Jacob | director | C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022 |
Peter J Graham | officer: See Remarks | 315 E. 72ND ST., APT 5E, NEW YORK NY 10021 |
Peter Greenleaf | director | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Anton Gueth | director | |
Robert F Apple | director, officer: President & CEO | C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422 |
Marvin Samson | director | |
Jacques Gonella | director | C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341 |
James Patrick Tursi | officer: EVP, Chief Medical Officer | 106 ASHLEY COURT, MOORESTOWN NJ 08057 |
Keith E Muckenhirn | officer: VP/Controller & Interim CFO | C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447 |
From GuruFocus
By Business Wire Business Wire • 05-05-2022
By PRNewswire PRNewswire • 05-16-2022
By PRNewswire PRNewswire • 05-22-2022
By GuruFocusNews GuruFocusNews • 04-13-2022
By PRNewswire PRNewswire • 04-28-2022
By Business Wire Business Wire • 05-02-2022
By PRNewswire PRNewswire • 05-12-2022
By GuruFocus Research GuruFocus Editor • 07-29-2022
By PRNewswire PRNewswire • 04-20-2022
By PRNewswire PRNewswire • 05-26-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.